- Home
- PHUN vs BEAT Comparison
PHUN vs BEAT Comparison
Compare PHUN & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | BEAT |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | EDP Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 53.2M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | PHUN | BEAT |
|---|---|---|
| Price | $2.04 | $0.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $7.25 | $5.63 |
| AVG Volume (30 Days) | 131.6K | ★ 610.9K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,883,000.00 | N/A |
| Revenue This Year | $89.86 | N/A |
| Revenue Next Year | N/A | $315.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.57 | N/A |
| 52 Week Low | $1.56 | $0.54 |
| 52 Week High | $3.88 | $4.00 |
Technical Indicators
Market Signals| Indicator | PHUN | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 41.90 |
| Support Level | $1.79 | $0.81 |
| Resistance Level | $2.28 | $1.28 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 42.11 | 5.62 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.